Nasdaq

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

PHILADELPHIA, Aug. 6, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing ...
Nasdaq

Atea Pharmaceuticals presents three HCV poster presentations at AASLD

Atea Pharmaceuticals (AVIR) announced it presented three poster presentations supporting the combination of bemnifosbuvir and ruzasvir as a potential treatment for hepatitis C virus, or HCV. The ...
Morningstar

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

NORCROSS, Ga., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the presentation of ...
Business Wire

Study Highlighting ENDRA Life Sciences’ TAEUS Technology in Patients with High BMI to be Presented at AASLD’s The Liver Meeting ® 2024

ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS ®), today announced the acceptance of a poster titled ...
Seeking Alpha

Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024

PHILADELPHIA, Nov. 17, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (CARM) (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and ...
KELOLAND News

Carisma Therapeutics Announces Upcoming Presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2024

The poster presented at AASLD 2024 will be available online in the "Publications" section of Carisma's website at https://carismatx.com/technology/publications ...
Business Insider

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts ...